These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32554846)

  • 61. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma.
    Miyazaki K; Noda N; Okada S; Hagiwara Y; Miyata M; Sakurabayashi I; Yamaguchi N; Sugimura T; Terada M; Wakasugi H
    Biotherapy; 1998; 11(4):277-88. PubMed ID: 9950104
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
    Abdel-Razik A; Elhelaly R; Elzehery R; El-Diasty A; Abed S; Elhammady D; Tawfik A
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):599-605. PubMed ID: 26741637
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis.
    Lin ZY; Wang LY; Yu ML; Chen SC; Chuang WL; Hsieh MY; Tsai JF; Chang WY
    J Gastroenterol Hepatol; 2000 Apr; 15(4):417-21. PubMed ID: 10824887
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients.
    Zekri AR; Youssef AS; Bakr YM; Gabr RM; El-Rouby MN; Hammad I; Ahmed EA; Marzouk HA; Nabil MM; Hamed HA; Aly YH; Zachariah KS; Esmat G
    Asian Pac J Cancer Prev; 2015; 16(3):1281-7. PubMed ID: 25735368
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Serum DLK1 is a potential prognostic biomarker in patients with hepatocellular carcinoma.
    Li H; Cui ML; Chen TY; Xie HY; Cui Y; Tu H; Chen FH; Ge C; Li JJ
    Tumour Biol; 2015 Nov; 36(11):8399-404. PubMed ID: 26018510
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients.
    Guarino M; Di Costanzo GG; Gallotta A; Tortora R; Paneghetti L; Auriemma F; Tuccillo C; Fassina G; Caporaso N; Morisco F
    Scand J Clin Lab Invest; 2017 Oct; 77(6):448-453. PubMed ID: 28609160
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.
    Motawi TK; Shaker OG; El-Maraghy SA; Senousy MA
    PLoS One; 2015; 10(9):e0137706. PubMed ID: 26352740
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Correlation Between Circulating Betatrophin and Insulin Resistance in General Population: A Meta-Analysis.
    Xu J; Lin Y; Zhou H; Zhao L; Xiang G
    Horm Metab Res; 2017 Oct; 49(10):760-771. PubMed ID: 28931172
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response.
    Mücke VT; Thomas D; Mücke MM; Waidmann O; Zeuzem S; Sarrazin C; Pfeilschifter J; Vermehren J; Finkelmeier F; Grammatikos G
    Liver Int; 2019 Nov; 39(11):2174-2183. PubMed ID: 31207039
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis.
    Ulu M; Alacacioglu A; Yuksel E; Pamukk BO; Bozkaya G; Ari A; Yuksel A; Sop G; Alacacioglu I
    Saudi J Gastroenterol; 2015; 21(1):47-50. PubMed ID: 25672239
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High-intensity interval training improved fasting blood glucose and lipid profiles in type 2 diabetic rats more than endurance training; possible involvement of irisin and betatrophin.
    Amri J; Parastesh M; Sadegh M; Latifi SA; Alaee M
    Physiol Int; 2019 Sep; 106(3):213-224. PubMed ID: 31578075
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Betatrophin: no relation to glucose metabolism or weight status in obese children before and after lifestyle intervention.
    Roth CL; Elfers C; Lass N; Reinehr T
    Pediatr Diabetes; 2017 Sep; 18(6):485-491. PubMed ID: 27402552
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Serum transforming growth factor alpha level as a marker of hepatocellular carcinoma complicating cirrhosis.
    Tomiya T; Fujiwara K
    Cancer; 1996 Mar; 77(6):1056-60. PubMed ID: 8635123
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
    Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
    World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients.
    Shaheen NMH; Zayed N; Riad NM; Tamim HH; Shahin RMH; Labib DA; ELsheikh SM; Moneim RA; Yosry A; Khalifa RH
    Virus Res; 2018 Aug; 255():77-84. PubMed ID: 30003924
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effect of 4-week endurance training on serum levels of irisin and betatrophin in streptozotocin- induced diabetic rats.
    Sadeghipour HR; Yeganeh G; Zar A; Salesi M; Akbarzadeh S; Bernardi M
    Arch Physiol Biochem; 2023 Jun; 129(3):575-581. PubMed ID: 33270481
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver.
    Cho HJ; Kim B; Lee JD; Kang DR; Kim JK; Lee JH; Shin SJ; Lee KM; Yoo BM; Lee KJ; Kim SS; Cheong JY; Cho SW
    Am J Gastroenterol; 2017 Mar; 112(3):460-470. PubMed ID: 27779194
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Vitamin D modifies the associations between circulating betatrophin and cardiometabolic risk factors among youths at risk for metabolic syndrome.
    Fu J; Hou C; Li L; Feng D; Li G; Li M; Li C; Gao S; Li M
    Cardiovasc Diabetol; 2016 Oct; 15(1):142. PubMed ID: 27716289
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma.
    Liu T; Yao M; Liu S; Wang L; Wang L; Hou J; Ma X; Jia J; Zhao J; Zhuang H; Lu F
    Oncotarget; 2017 Mar; 8(10):16498-16506. PubMed ID: 28157705
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.